The application safety of a new combined drug, which is in a preclinical testing stage, is studied. The drug contains an active analgesic tramadol and strong spasmolytic drotaverin. The combination exposes the analgesic properties in spastic moderate pain, is referred to the III class of toxicity, non-allergenic. The combined drug with introabdiminal introduction to animals decreased the locomotor and research function and moderately weakened an emotional component of the reaction, without a teratogenic and embryotoxic action.
